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Evidence for improved prognosis 
of colorectal cancer diagnosed 
following the detection of iron 
deficiency anaemia
Orouba Almilaji1,2*, Sally D. Parry1, Sharon Docherty2 & Jonathon Snook1
Iron deficiency anaemia (IDA) is common in colorectal cancer (CRC), especially, in right-sided CRC 
which is known to have an overall worse prognosis. The associations between diagnostic pathway 
(Bowel Cancer Screening Programme (BCSP), IDA, symptomatic) and tumour side/stage was assessed 
using logistic regression models in 1138 CRC cases presenting during 2010–2016 at a single secondary-
care centre in the UK. In the IDA sub-group, the relationship between CRC stage and the event of 
having a blood count prior to CRC diagnosis was examined using Bayesian parametric survival model. 
IDA was found as the only significant predictor of right-sided CRC (OR 10.61, 95% CI 7.02–16.52). 
Early-stage CRC was associated with both the IDA (OR 1.65, 95% CI 1.18–2.29) and BCSP pathway 
(OR 2.42, 95% CI 1.75–3.37). At any age, the risk of detecting CRC at late-stage was higher in those 
without a previous blood count check (hazard ratio 1.53, 95% credibility interval 1.08–2.14). The 
findings of this retrospective observational study suggest a benefit from diagnosing CRC through the 
detection of IDA, and warrant further research into the prognosis benefit of systematic approach to 
blood count monitoring of the at-risk population.
Abbreviations
CRC  Colorectal cancer
IDA  Iron deficiency anaemia
Hb  Blood haemoglobin concentration
GP  General Practitioner
BCSP  Bowel Cancer Screening Programme
OR  Odds ratio
CI  Confidence interval
Colorectal cancer (CRC) is the fourth common cancer in the United Kingdom, accounting for 12% of all new 
cases; and the second common cause of cancer-related death, responsible for about 10% of all cancer deaths in 
the  UK1,2. Although the outlook is slowly improving, the 5‐year survival rate for CRC is still relatively poor at 
58% because most CRC cases in the UK are diagnosed at late  stage3,4.
It has been recognized that those with more advanced CRC at diagnosis have a worse prognosis, leading 
to the development of the TNM staging system for CRC 5. The association is striking—treated 5-year survival 
ranges from over 90% for stage I disease down to about 10% for stage IV  disease1,4. The fact that tumour stage 
generally increases progressively with time, highlighting the importance of early diagnosis. Unfortunately, CRC 
may not cause symptoms until the disease is already advanced, and when symptoms do develop there is some-
times reluctance to seek medical advice. The consequence of these delays is that many cases of CRC present at 
a late stage, with a correspondingly high mortality rate. The focus over recent years has therefore been on early 
diagnosis by screening of the pre-symptomatic at-risk  population1,6.
The English Bowel Cancer Screening Programme (BCSP) was developed with the aim of reducing the mortal-
ity rate by both earlier detection of CRC and removing polyps which if left untreated might advance to  cancer6. 
The BCSP is based on the biennial offer of a faecal occult blood test to all in the population aged 60–74, with a 
view to colonoscopy if positive.
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Bowel cancer screening has been shown to reduce the mortality rate of CRC by about 15% with faecal occult 
blood  testing7,8, probably because cases were detected at an earlier  stage1,9. The proportion of CRCs diagnosed 
at early stage (I or II) was about 64% for the BCSP in 2017, compared to 47% for GP referrals and 32% for those 
presenting as emergency  admissions10. However only about 10% of all CRCs countrywide are detected through 
the  BCSP11. The relatively low proportion of screened detected cancers probably relates to a number of factors, 
including low population uptake (less than 50% in some areas) and limited sensitivity of the initial screening  test9.
Overall about a third of CRCs occur in the right colon, and these differ in a number of important respects 
from those found in the left  colon1,12. Right-sided CRCs tend to present with larger tumours at a more advanced 
stage, and a correspondingly worse  prognosis12–18. They are also strongly associated with the finding of iron 
deficiency anaemia (IDA) at  presentation19–23, believed to be due to chronic low-grade loss of (iron-rich) blood 
from the tumour bed, resulting in the slowly progressive depletion of body iron stores. IDA often occurs before 
any other clinical manifestations of CRC 24, and as the development of IDA is gradual it may precede the diag-
nosis of CRC by up to 2  years25. This provides a window of opportunity for the detection of CRC earlier in the 
disease course, particularly for tumours of the right colon, and is the basis of the recommendation for urgent 
investigation of unexplained IDA in the at-risk  population26,27.
The study reported here is based on the analysis of a large dataset of patients with CRC presented through 
different diagnostic pathway at a single centre, and the objectives were twofold. First, to compare the effect of 
the three major diagnostic routes for CRC—the IDA, BCSP, and symptomatic pathways—on the stage and side 
of CRC. Second, to explore the scale of the missed opportunity for earlier diagnosis of CRC through the IDA 
pathway, by assessing the prevalence and results of blood counts prior to CRC diagnosis in the IDA pathway 
sub-group, and comparing the relationship between prior blood count event and the risk of late-stage disease 
at diagnosis.
Methods
This study is a retrospective observational study involved statistical analysis of anonymised secondary clinical 
data on the Poole Hospital CRC MDT database for the years 2010 to 2016 inclusive. Assuming the smallest 
effect size (0.1), and significance level = 0.05, the sample size was estimated to be around 967 when power = 80%, 
and around 1268 when power = 90%. The Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) guidelines were used to ensure the reporting of this study. Since this is an observational study, and 
simply involved the analysis of anonymised secondary clinical data, formal ethical/institutional approvals, con-
sent to participate/publish were not required.
The association between stage/side and presentation pathway. The first part of this study 
involved the statistical analysis of 1258 CRC cases. The data was scrutinized in 2018 for the purposes of a service 
audit and included:
• age at diagnosis;
• sex;
• haemoglobin concentration (Hb) at presentation;
• presentation pathway (IDA, BCSP or symptomatic);
• tumour stage (of the most advanced if synchronous lesions present);
• tumour number, histology and location(s).
Iron deficiency was defined by transferrin saturation < 15% and/or serum ferritin less than the lower labora-
tory limit of normal at the time of the analysis. The symptomatic group comprised cases with symptoms relating 
directly to the underlying CRC (other than symptomatic anaemia) that resulted in GP referral or emergency 
admission to secondary care. Patients with both bowel symptoms and IDA were allocated to a presentation 
pathway based on which was felt to be the dominant feature—in a few cases this was rather arbitrary, but the 
allocation was made without knowledge of tumour site or stage.
The diagnosis of CRC was established by standard clinical investigation including colonoscopy, and CT scan-
ning. Tumours were graded according to the simplified TNM staging  system5 based on the initial radiological 
appearances, modified in the light of subsequent surgical and pathological findings where available. For the 
purposes of the analysis, stage I and II CRCs were combined into one category—early stage; whilst stage III and 
IV CRCs were combined as a second category—late stage. CRCs located at or beyond the splenic flexure were 
considered left-sided, and those proximal to splenic flexure right-sided. Eight cases had synchronous CRCs, and 
for the purposes of this study they were considered right-sided if any tumour was proximal to the splenic flexure.
The exclusion criteria were (a) incomplete records (17 cases), (b) second entry due to metachronous CRC (7), 
(c) other neoplastic diagnoses such as stromal tumours, small bowel carcinoma, neuroendocrine tumours, and 
anal carcinoma (35), (d) non-incident presentation/diagnosis made at another hospital (27), and (e) diagnosis 
of CRC on cancer follow-up or as an incidental finding on a scan undertaken for some unrelated reason (34). 
When no histological confirmation was found, cases were included only if the radiological features were regarded 
as characteristic of CRC, and they were managed as such clinically.
The effects of age, sex, Hb, and presentation pathway on tumour stage (early/late) or side (left/right) were 
analysed using simple binary logistic regression models run for each of the predictors separately, with stage or 
side as the outcome. When any significant association was found (p < 0.05), the predictor was added to a mul-
tivariable logistic regression model. Due to correlations with particular presentation pathways (such as in the 
case of BCSP and age, and IDA and Hb), only simple regression models were built for age and Hb. Statistical 
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methods used to check the validity of the fitted logistic regression models and the goodness of fit are shown in 
(Table S1, Supplementary Information).
The association between prior blood test event and stage. The second part of the study involved a 
detailed assessment of the 171 IDA sub-group from all the 1258 cases dataset. An arbitrary “presentation period” 
was defined as the 3 months immediately prior to the date of CRC diagnosis. The anonymised data for each 
subject included whether a blood count had been checked in the 3 years prior to the start of their presentation 
period, and if so, the date and Hb result for the last blood count in this window. On the basis of published litera-
ture regarding temporal changes in blood count prior to the diagnosis of CRC 26, an arbitrary window of 2 years 
was taken as the basis of comparison for this study.
A proportional hazards parametric survival model was employed to estimate the effect of previous blood 
count testing (done/not done) on the onset time of late-stage disease in the IDA sub-group using current status 
data. Current status data consisted of (a) observation time (CRC diagnosis time) and (b) whether the observa-
tion time was smaller or larger than the time to late-stage CRC. Diagnosis time was assumed to be independent 
of late-stage CRC onset time, and survival time (free of late-stage CRC i.e. diagnosed with early stage CRC) to 
equal age (in years).
The endpoint of interest was “time to late-stage CRC”. So, if patient i was investigated at age Ci and late-stage 
CRC diagnosed, the time of onset was recorded as the interval [0, Ci]. If early-stage CRC was diagnosed, then 
the time of late-stage onset was recorded as the interval [Ci, ∞].
The Weibull distribution was specified as the baseline parametric distribution because it allows for constant, 
increasing, or decreasing hazard rates. To approximate the posterior distribution parameters, four Markov Chain 
Monte Carlo (MCMC) methods were used (sample size per chain was 1000). As current status data was unin-
formative, we incorporated prior information into the analysis by extending the parametric model to Bayesian 
framework. The prior information was based on the following assumptions (a) hazard rates of late-stage disease 
do not decrease with age and (b) without intervention, all early-stage CRCs would progress to late-stage within 
10 years. To incorporate (a) the shape parameter was constrained to be > 1, whilst for (b), we set a maximum 
possible time equal to the age of the patient plus 10 years instead of the upper end of the interval (∞). Statisti-
cal assessments of validity and goodness of fit of the models were based on the method outlined in (Table S1, 
Figs. S1, S2, Supplementary Information).
The methods used in this study were guided by previous relevant  publications28–32. R (version 3.6.1) and 
RStudio (version 1.2.5001) were used to run the statistical analyses and to produce the descriptive statistics, 
and graphs.
Ethics declarations. Retrospective analysis of anonymised secondary data, formal research ethics approval 
was not required.
Results
The association between stage/side and presentation pathway. After tidying the database and 
applying the exclusion criteria, 1138 complete cases were available for detailed analysis. Of these, 90% had histo-
logically confirmed colorectal adenocarcinoma, and most of the remainder had high-grade dysplasia on biopsy, 
undifferentiated carcinoma, or signet cell carcinoma. As shown in Table 1, almost 70% of cases presented via the 
symptomatic pathway, with about 15% each through the IDA and BCSP routes. Overall, 45% of cases presented 
with early-stage disease, and 39% with right-sided tumours.
As anticipated, the BCSP group were more likely to be male, and to be younger. The proportion with right-
sided tumours was markedly higher in the IDA group and slightly reduced in the BCSP group.
By crude comparison with the symptomatic group, there was a greater percentage of early-stage CRCs in 
both of the other groups (Fig. 1).
Four binary logistic regression models were constructed, and their findings are summarised in Table 2.
In model A, analysis revealed that sex and presentation pathway were both strongly significant predictors 
of tumour side. The final multiple binary logistic regression model was therefore constructed according to the 
formula (left-side CRC as reference category):
Table 1.  Descriptive statistics of the CRC dataset divided by presentation pathway (IDA iron deficiency 
anaemia, BCSP Bowel Cancer Screening Programme, and symptomatic group).
IDA BCSP Symptomatic
Number n (%) 171 (15.0%) 187 (16.4%) 780 (68.6%)
Sex ratio M/F 1.1 1.5 1.3
Age (years) Median (Q1–Q3) 78 (71–86) 68 (64–71) 75 (64–83)
Hb at diagnosis (g/l) Median (Q1–Q3) 89 (80–100) 138 (126–147) 124 (106–140)
Early stage (I + II) n (%) 89 (52.0%) 115 (61.5%) 310 (39.7%)
Right-sided n (%) 141 (82.5%) 56 (29.9%) 245 (31.4%)
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The odds of right-sided CRC were about 11 times higher for the IDA pathway than the symptomatic one, 
whilst the BCSP route was not a significant predictor of right-sided CRC. CRCs were 94% more likely to be 
right-sided in females compared to males.
In model B, Hb was found to be a very significant negative predictor of right-sided CRC—for each unit (g/l) 
decrease in Hb, there was about a 5% increase in the odds of right-sided CRC.
Model C showed that age is also a very significant positive predictor of right-sided CRC—for each rising year 
of age, the odds of right-sided CRC increased by about 4%.
In model D, statistical analysis showed that only presentation pathway was a significant predictor of early-stage 
CRC. The association between tumour side and stage is not statistically significant (p = 0.07). The final binary 
logistic regression model was therefore constructed according to the formula (late stage as reference category):
The findings indicate that IDA was a significant positive predictor of early stage CRC. Results also show CRCs 
presenting through the IDA and BCSP routes are 65% and 142% respectively more likely to be diagnosed at early 
stage, as compared to the symptomatic pathway. Statistical assessment of validity and goodness of fit of the logistic 
regression models was satisfactory (based on the criteria outlined in Table S1—Supplementary Information).
Figure 1.  The distribution of tumour stage by presentation pathway.
Table 2.  Summary of logistic regression analyses showing variables predictive of right-sided CRC (models 
A–C) and early-stage CRC (model D).
Model Outcome Predictor OR (95% CI) P value
A Right-sided CRC 
Presentation (IDA) 10.61 (7.02–16.52)  < 0.0001
Presentation (BCSP) 0.95 (0.67–1.35) 0.78
Sex (female) 1.94 (1.49–2.53)  < 0.0001
B Right-sided CRC Hb (g/l) 0.95 (0.94–0.96)  < 0.0001
C Right-sided CRC Age (years) 1.04 (1.03–1.05)  < 0.0001
D Early-stage CRC 
Presentation (IDA) 1.65 (1.18–2.29) 0.003
Presentation (BCSP) 2.42 (1.75–3.37)  < 0.0001
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The association between prior blood test event and stage. Figure  2 shows the cumulative per-
centage prevalence of blood counts over the 3 years prior to the presentation period for CRC, for the 171 cases 
presenting via the IDA pathway.
In the 2 years prior to diagnosis of CRC, 31% of did not have a record of any blood count, and a further 22% 
had an abnormally low blood count (Hb < 110 g/l) which did not result in immediate referral. Most of these 
abnormal results were recorded in the 12 months prior to the presentation period.
Descriptive statistics for the IDA group broken down by the result of the last blood count in the 2 years prior 
to the presentation window of CRC are shown in Table 3. There were trends towards those with ‘blood test not 
done’ being younger, more likely to have right-sided CRC, and less likely to have early-stage disease.
Bayesian Weibull regression showed that the posterior baseline survival distribution of IDA patients with 
early-stage CRC at diagnosis (i.e. not having reached late-stage disease) decreased with increasing age. This sur-
vival figure fell from 80% at age 60 to about 35% at age 80 (Fig. 3a); a. Analysis also revealed that having a prior 
blood test (regardless of result) was significantly related to time to late-stage disease (mean (sd): 0.66 (0.18), 95% 
credibility interval 0.46–0.93). Looked at the other way, the hazard ratio for detecting CRC at late-stage was 53% 
higher in those without a previous blood count (1.53, 95% credibility interval 1.08–2.14).
The posterior median onset time of late-stage CRC in those with a blood count in the preceding 2 years was 
75 years (95% credibility interval 72–78). This was 5 years later than the median onset time of 70 years of age 
(95% credibility interval 65–74) for those without a blood count. This implies that at a given age, the probability 
that CRC is detected at an early-stage is higher in those with a previous blood count (Fig. 3b).
Figure 2.  The cumulative percentage prevalence of blood count checks in the 12, 24 and 36 months prior to the 
diagnosis of CRC in the IDA group, sub-divided according to the tumour stage (early/late) and Hb result (g/l).
Table 3.  Descriptive statistics for the IDA group (n = 171) by outcome of the last blood count in the 2 years 
prior to presentation with CRC.
Hb > 110 g/l Hb < 110 g/l Not done
Number n (%) 80 (47%) 38 (22%) 53 (31%)
Sex ratio M/F 1.5 0.7 1.1
Age (years) Median (Q1–Q3) 78 (75–85) 83 (77–88) 73 (66–83)
Hb at diagnosis (g/l) Median (Q1–Q3) 94 (85–102) 84 (71–92) 87 (74–99)
Early stage n (%) 44 (55.0%) 20 (52.6%) 25 (47.2%)
Right-sided n (%) 65 (81.2%) 30 (78.9%) 46 (86.8%)
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Discussion
Our results demonstrate that during the 7-year study period, just over 30% of CRCs were diagnosed via either 
the IDA or BCSP pathway, with similar numbers in each. Comparison with national data reveals a similar pro-
portion of early-stage disease diagnosed through the symptomatic pathway, at around 40%10. The figure for the 
BCSP pathway is slightly lower than the national figure (62% v 64%), but this may reflect the higher proportion 
of right-sided cancers detected (30% v 23%)9,10.
We have confirmed previous observations that IDA is strongly associated with right-sided CRC, but the 
striking finding from our study is that diagnosis through a contemporary IDA pathway has the potential to 
downstage the disease, as previously demonstrated for the BCSP  pathway9. This is in contrast to reports in the 
literature suggesting that IDA is a marker of poor prognosis in CRC 22,23,33,34. The reasons why our findings dif-
fer from those of some historical studies may include issues of confounding and diagnostic delay. Firstly, the 
risk of confounding arises from the strong association between IDA and right-sided CRC—a pattern of disease 
which is associated with later diagnosis at a more advanced stage, and a correspondingly poorer  prognosis12–18. 
Secondly, the diagnosis of CRC through the IDA pathway has been beset by delays resulting in late diagnosis of 
CRC and so a poor  prognosis35–39.
In years past major delays at three points in the pathway of CRC diagnosis through the detection of IDA 
were all too common, and the cumulative effect of these delays may have been a major contributor to the his-
torical association of IDA with poor prognosis in CRC 35–39. The first is confirmation of IDA on a blood test—a 
particular issue as even severe anaemia may not cause appreciable symptoms. The second is lack of awareness of 
the significance of IDA as a marker of underlying malignancy, and therefore of the importance of swift referral 
for investigation. The third is the time between referral and an adequate diagnostic examination of the (right) 
colon. Survival in anaemic CRC appears to be inversely related to this last  delay39.
Various developments over recent years have had a major bearing on these delays. Firstly, routine blood 
count checks in the at-risk population have become much more frequent and widespread—the rate of blood 
count testing increased progressively in the UK between 2000 and 2015, from approximately 160 to 430 per 1000 
population per  annum40.
Secondly, much has been done to accelerate the referral and comprehensive investigation of patients found 
to have IDA, particularly those at risk of CRC. This includes education in primary care, national guidelines 
encouraging fast-track  referral26,27, and the development of dedicated IDA triage services in secondary care—such 
as the IDA Clinic at  Poole41,42, which was incidentally operational throughout the years of this study. Finally, 
gastroenterology speciality groups have introduced quality initiatives to improve the diagnostic yield of inves-
tigation, particularly in the right  colon43.
The strengths of this study are the novelty of examining the association between the event of having prior 
blood count check and the CRC stage in IDA patients, and inclusion of a BCSP CRC group as a positive control. 
Limitations include the uncertain applicability of a single centre experience to other populations, and being a 
retrospective analysis, our inability to control the size of the study subgroups or to incorporate other variables 
that could impact the prognosis in CRC. In fact, the major potential constraint of the study was the use of stage/
side as the only markers of prognosis in CRC. We feel however that this methodology is justified because the link 
between stage/side and prognosis is so  strong1,4, and this view is supported by the results for the BCSP group, 
which fit well with the established improvement in prognosis with this  programme7–9,44. Nonetheless, further 
studies are clearly warranted to corroborate the findings.
With correction for confounding and a reduction in diagnostic delays, our results suggest that CRC in the 
right colon may be detected at earlier stage with a correspondingly better prognosis. This observation strengthens 
the case for the inclusion of monitoring for IDA in the repertoire of screening approaches for the early diagnosis 
of CRC. Currently however there is no systematic process for routinely checking blood counts in the at-risk 
population, despite the universal presence of the necessary laboratory infra-structure.
Figure 3.  Posterior survival distributions for the IDA group, showing (a) the baseline survival probability at 
any given time S(t), with dashed lines representing the credibility interval, and (b) the survival probabilities for 
sub-groups categorised by whether a blood count was done in the two years prior to the presentation window.
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Bearing in mind that the development of IDA is a gradual process prior to the diagnosis of CRC, our results 
suggest that there may be scope for further improvement in how we screen for bowel cancer. Of those diagnosed 
with CRC via the IDA pathway, some 31% had not had a blood count in the 2 years prior to diagnosis, whilst a 
further 22% had a low blood count—that in retrospect may perhaps have been indicative of undiagnosed CRC. 
Our results also suggest that the median onset age of late-stage CRC in those with a previous blood count is 
about 5 years older than in those without, so that for a given age, the proportion of CRCs detected at early stage 
is higher. This is an interesting observation for which there are various possible explanations, but we feel that 
confounding is perhaps the most likely—individuals who avoid medical care are inherently less likely to have a 
blood test, and also less likely to present early with their undiagnosed CRC.
Nevertheless, we feel that a strong case can be made for formally recommending a blood count test on perhaps 
an annual basis in the at-risk population—with follow-up iron studies for those with detected anaemia. Blood 
count checks have an advantage over the current CRC screening modalities of stool testing or sigmoidoscopy 
in being more acceptable to many people. However, the recommendation would be to introduce blood count 
checks as a screening test complementary to the current BCSP, not an alternative. The logic to this is that IDA 
screening would be expected to predominantly detect right-sided CRC, whilst the current BCSP predominantly 
targets left-sided CRC, with the suspicion that it may be less effective at picking up right-sided  lesions9,44.
In conclusion, our findings suggest prognostic benefit from diagnosing CRC through the detection of IDA, 
and that IDA screening is currently sub-optimal. These observations strengthen the case for a systematic approach 
to blood count monitoring of the at-risk population.
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